Chemical Information
Antiviral agent ID	DrugRepV_7665
Antiviral agent name	Diiodohydroxyquinoline
IUPAC Name	5,7-diiodoquinolin-8-ol
SMILES (canonical)	C1=CC2=C(C(=C(C=C2I)I)O)N=C1
Molecular Formula	C9H5I2NO
Molecular Weight (g/mol)	396.95
InChl	InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
Structural Information
Clinical Information
Category	Genito Urinary System And Sex Hormones
Primary Indication (Clinical trial phases)	Approved
Biological Information
Primary Indication (Disease Category)	Non Infectious Disease
Primary Indication (Disease)	Used in the treatment of amoebiasis.
Secondary Indication	SARS Coronavirus-2 (SARS-CoV-2) 2
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	VeroE6
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Duration of drug delivery)	48 hours
Secondary Indication (Drug concentration)	1.38 μM
Secondary Indication (Cell based assay)	Plaque reduction assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)	>100 μM
Reference	Yuan S, Chan JFW, Chik KKH, Chan CCY, Tsang JOL, Liang R, Cao J, Tang K, Chen LL, Wen K, Cai JP, Ye ZW, Lu G, Chu H, Jin DY, Yuen KY..Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system..Pharmacol Res. 2020 May 28;159:104960. doi: 10.1016/j.phrs.2020.104960. PMCID: PMC7254006. PMID:32473310
Comment	At 48 hpi, the 50 % cytotoxic concentrations (CC50) of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and bexarotene were > 100 μM, > 100 μM, 92.35 μM, and 38.21 μM, respectively